Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2006

01-07-2006 | Preclinical study

Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer

Authors: Lukas A. Hefler, Christoph Grimm, Tilmann Lantzsch, Dieter Lampe, Heinz Koelbl, Antje Lebrecht, Georg Heinze, Clemens Tempfer, Alexander Reinthaller, Robert Zeillinger

Published in: Breast Cancer Research and Treatment | Issue 2/2006

Login to get access
Metadata
Title
Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer
Authors
Lukas A. Hefler
Christoph Grimm
Tilmann Lantzsch
Dieter Lampe
Heinz Koelbl
Antje Lebrecht
Georg Heinze
Clemens Tempfer
Alexander Reinthaller
Robert Zeillinger
Publication date
01-07-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9143-2

Other articles of this Issue 2/2006

Breast Cancer Research and Treatment 2/2006 Go to the issue

Epidemiology

No nodal cutoff in node-positive breast cancer women treated with mastectomy

Clinical trial

Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer

Epidemiology

Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women

Preclinical study

Expression of “Spot 14” (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker

Clinical trial

Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52

Preclinical study

High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits